Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Conditions:   Age Range ≥16 Years, Gender Unlimited;   Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma;   Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed;   At Least One Positive Lesion According to the 20 14 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma;   ECOG Physical Status Score is 0-3;   The Researchers Judged That Life Expectancy Was at Least Three Months;   Understand and Voluntarily Sign Written Informed Consent Intervention:   Drug: TR2-ICE Sponsors:   Affiliated Hospital to Academy of Military Medical Sciences;   Beijing Cancer Hospital;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials